Cargando…
PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428890/ http://dx.doi.org/10.1097/01.HS9.0000976044.29005.fd |
| _version_ | 1785090578822725632 |
|---|---|
| author | Linton, Kim Doorduijn, Jeanette El-Sharkawi, Dima Mous, Rogier Forconi, Francesco Lewis, David Gleeson, Mary Riches, John Mckay, Pam Stevens, Wendy Injac, Sarah G Collins, Graham P |
| author_facet | Linton, Kim Doorduijn, Jeanette El-Sharkawi, Dima Mous, Rogier Forconi, Francesco Lewis, David Gleeson, Mary Riches, John Mckay, Pam Stevens, Wendy Injac, Sarah G Collins, Graham P |
| author_sort | Linton, Kim |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428890 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104288902023-08-17 PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES Linton, Kim Doorduijn, Jeanette El-Sharkawi, Dima Mous, Rogier Forconi, Francesco Lewis, David Gleeson, Mary Riches, John Mckay, Pam Stevens, Wendy Injac, Sarah G Collins, Graham P Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428890/ http://dx.doi.org/10.1097/01.HS9.0000976044.29005.fd Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Linton, Kim Doorduijn, Jeanette El-Sharkawi, Dima Mous, Rogier Forconi, Francesco Lewis, David Gleeson, Mary Riches, John Mckay, Pam Stevens, Wendy Injac, Sarah G Collins, Graham P PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title | PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_full | PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_fullStr | PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_full_unstemmed | PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_short | PB2331: AN ONGOING FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES |
| title_sort | pb2331: an ongoing first-in-human phase 1 trial of nx-5948, an oral bruton’s tyrosine kinase (btk) degrader, in patients with relapsed/refractory b cell malignancies |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428890/ http://dx.doi.org/10.1097/01.HS9.0000976044.29005.fd |
| work_keys_str_mv | AT lintonkim pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT doorduijnjeanette pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT elsharkawidima pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT mousrogier pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT forconifrancesco pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT lewisdavid pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT gleesonmary pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT richesjohn pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT mckaypam pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT stevenswendy pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT injacsarahg pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies AT collinsgrahamp pb2331anongoingfirstinhumanphase1trialofnx5948anoralbrutonstyrosinekinasebtkdegraderinpatientswithrelapsedrefractorybcellmalignancies |